Red Blood Cell Omics and Machine Learning in Transfusion Medicine: Singularity Is Near
- PMID: 37434999
- PMCID: PMC10331163
- DOI: 10.1159/000529744
Red Blood Cell Omics and Machine Learning in Transfusion Medicine: Singularity Is Near
Abstract
Background: Blood transfusion is a life-saving intervention for millions of recipients worldwide. Over the last 15 years, the advent of high-throughput, affordable omics technologies - including genomics, proteomics, lipidomics, and metabolomics - has allowed transfusion medicine to revisit the biology of blood donors, stored blood products, and transfusion recipients.
Summary: Omics approaches have shed light on the genetic and non-genetic factors (environmental or other exposures) impacting the quality of stored blood products and efficacy of transfusion events, based on the current Food and Drug Administration guidelines (e.g., hemolysis and post-transfusion recovery for stored red blood cells). As a treasure trove of data accumulates, the implementation of machine learning approaches promises to revolutionize the field of transfusion medicine, not only by advancing basic science. Indeed, computational strategies have already been used to perform high-content screenings of red blood cell morphology in microfluidic devices, generate in silico models of erythrocyte membrane to predict deformability and bending rigidity, or design systems biology maps of the red blood cell metabolome to drive the development of novel storage additives.
Key message: In the near future, high-throughput testing of donor genomes via precision transfusion medicine arrays and metabolomics of all donated products will be able to inform the development and implementation of machine learning strategies that match, from vein to vein, donors, optimal processing strategies (additives, shelf life), and recipients, realizing the promise of personalized transfusion medicine.
Keywords: Machine learning; Omics; Red blood cells; Storage; Transfusion.
Copyright © 2023 by The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
A.D. is a founder of Omix Technologies Inc. and Altis Biosciences LLC, a consultant for Hemanext Inc., Macopharma Inc., and Forma Therapeutics.
References
-
- Li N, Arnold DM, Down DG, Barty R, Blake J, Chiang F, et al. From demand forecasting to inventory ordering decisions for red blood cells through integrating machine learning statistical modeling and inventory optimization. Transfusion. 2022 Jan;62((1)):87–99. - PubMed
-
- Choorapoikayil S, Hof L, Old O, Steinbicker A, Meybohm P, Zacharowski K. How do I/we forecast tomorrow's transfusion? A focus on recipients' profiles. Transfus Clin Biol. 2023;30((1)):27–30. - PubMed
-
- Zhang Z, Navarese EP, Zheng B, Meng Q, Liu N, Ge H, et al. Analytics with artificial intelligence to advance the treatment of acute respiratory distress syndrome. J Evid Based Med. 2020 Nov;13((4)):301–312. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
